The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps

Gayatri B. Patel, Anju T. Peters*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

46 Scopus citations

Abstract

Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration–approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.

Original languageEnglish (US)
Pages (from-to)44-47
Number of pages4
JournalEar, Nose and Throat Journal
Volume100
Issue number1
DOIs
StatePublished - Jan 2021

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported my National Institute of Health grant T32AI083216; Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine; and by the Ernest Bazley Foundation.

Keywords

  • benralizumab
  • biologics
  • chronic rhinosinusitis with nasal polyps (CRSwNP)
  • dupilumab
  • mepolizumab
  • nasal polyps
  • omalizumab

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps'. Together they form a unique fingerprint.

Cite this